Comparable stake leader
BlackRock, Inc.
SEC ownership of Niagen Bioscience, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001386570.
Disclosed value leader
VANGUARD GROUP INC
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- NAGE on Nasdaq
- Parsed ownership sources
-
13F and 13D/G
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BlackRock, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001386570
- Issuer location
- Los Angeles, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Niagen Bioscience, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
VANGUARD GROUP INC
Comparable rows
50/50
Latest evidence
31 Mar 2026
13F
13D/G
Lead comparable stake: 5.2%
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 5.2%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
5.2%
VANGUARD GROUP INC
4.1%
SteelPeak Wealth, LLC
4.2%
ARROWSTREET CAPITAL, LIMITED PART...
3%
VANGUARD CAPITAL MANAGEMENT LLC
2.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
5.2%
from 13D/G
|
$17,073,839
3,871,619 shares
|
— | 31 Mar 2026 |
| VANGUARD GROUP INC |
13D/G
The Vanguard Group
|
4.1%
|
$20,902,127
3,286,498 shares
|
-$4,675,567 | 31 Dec 2025 |
| SteelPeak Wealth, LLC |
13F
Company
|
4.2%
|
$14,874,930
3,373,000 shares
|
— | 31 Mar 2026 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP |
13F
Company
|
3%
|
$10,488,907
2,378,437 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
2.7%
|
$9,478,312
2,149,277 shares
|
— | 31 Mar 2026 |
| Tieton Capital Management, LLC |
13F
Company
|
2.5%
|
$8,949,000
2,029,155 shares
|
— | 31 Mar 2026 |
| Qube Research & Technologies Ltd |
13F
Company
|
2.1%
|
$7,561,558
1,714,639 shares
|
— | 31 Mar 2026 |
| UBS Group AG |
13F
Company
|
1.8%
|
$6,198,392
1,405,531 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$45,616.
Buys
$45,616
Insiders: 1
Sells
$0
Insiders: 0
Net
+$45,616
Shares: +6,685
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 6,685
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 6,685 | 0 | $45,616 | $0 | +$45,616 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 21 reporting-owner rows connected to Niagen Bioscience, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
21
Largest Forms 3/4/5 holder
Chau Hoi Shuen Solina Holly
Net 12M change
+$45,616
Latest report
30 Jun 2026
Recent insider transactions for Niagen Bioscience, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Carlos Luis Lopez | NAGE | Common Stock | Award | 102.8% | 2,314 | 4,565 | 30 Jun 2026 | Direct | ||
| Ozan Pamir | NAGE | Common Stock | Award | 57.7% | 4,255 | 11,627 | 30 Jun 2026 | Direct | ||
| Robert N. Fried | NAGE | Common Stock | Award | 0.1% | 1,106 | 1,060,087 | 30 Jun 2026 | Direct | ||
| Wing Tak Wendy Yu | NAGE | Stock Option (right to buy) | Award | 31,746 | 31,746 | 24 Jun 2026 | Direct | |||
| Wang Yu Gary Ng | NAGE | Stock Option (right to buy) | Award | 31,746 | 31,746 | 24 Jun 2026 | Direct | |||
| Ann Cohen | NAGE | Stock Option (right to buy) | Award | 31,746 | 31,746 | 24 Jun 2026 | Direct | |||
| Kristin Patrick | NAGE | Stock Option (right to buy) | Award | 31,746 | 31,746 | 24 Jun 2026 | Direct | |||
| Hamed Shahbazi | NAGE | Stock Option (right to buy) | Award | 31,746 | 31,746 | 24 Jun 2026 | Direct | |||
| Steven D. Rubin | NAGE | Stock Option (right to buy) | Award | 31,746 | 31,746 | 24 Jun 2026 | Direct | |||
| Frank L. Jaksch Jr. | NAGE | Stock Option (right to buy) | Award | 31,746 | 31,746 | 24 Jun 2026 | Direct | |||
| Robert N. Fried | NAGE | Common Stock | Options Exercise | 1.92% | 20,000 | 1,058,981 | 24 Apr 2026 | Direct | ||
| Robert N. Fried | NAGE | Stock Options (right to buy) | Options Exercise | -100% | -20,000 | 0 | 24 Apr 2026 | Direct | ||
| Carlos Luis Lopez | NAGE | Employee Stock Options (right to buy) | Award | 41,420 | 41,420 | 19 Feb 2026 | Direct | |||
| Ozan Pamir | NAGE | Employee Stock Options (right to buy) | Award | 62,131 | 62,131 | 19 Feb 2026 | Direct | |||
| Robert N. Fried | NAGE | Employee Stock Options (right to buy) | Award | 503,937 | 503,937 | 19 Feb 2026 | Direct | |||
| Ozan Pamir | NAGE | Common Stock | Purchase | $15,210 | $6.85 | 2,220 | 2,220 | 14 Nov 2025 | The reported securities are held by the reporting person's spouse. | |
| Ozan Pamir | NAGE | Common Stock | Purchase | 153.6% | $30,406 | $6.81 | 4,465 | 7,372 | 14 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.